Pseudomonas aeruginosa spp are the most prevalent bacteria that cause nosocomial infections in hospitals. Most antibiotics, including novel new β-lactams, are already resistant to them, and they can become resistant during treatment, which can make the treatment fail. P. aeruginosa isolates from ICU patients who had Per-1 and VEB-1 were the main focus of this study. These two ESBLs are the two most common in ICU patients who had them. 50 isolates were gathered from Peshawar's LRH ICU facilities in the year 2021. The antibiotic susceptibility test was conducted in accordance with the Clinical and Laboratory Standards Institute's standards (CLSI). The combination disc test used to identify isolates that produce ESBLs. Ceftazidime MIC was determined using the agar dilution method using particular primers, the PER-1 and VEB-1 genes were detected using polymerase chain reaction (PCR). Fifty-six percent patients (n=40) male, whereas forty percent (n=25) were female. Augmentin (96.6%, n=61) and cefpodoxim (86.7%, n=55) resistance was found in the majority of ICU isolates. Fifty isolates (77%) tested positive for ESBL, with 94 percent (n=47) carrying the PER-1 gene and VEB-1 gene 52 percent (n=26). Ten isolates had blaPER1 and blaVEB1 present at the same time, and seven of them amplified all three genes. ESBL producers were found in a large number of ICU P. aeruginosa isolates. Although blaVEB1 and blaPER1 were found in a small number of isolates, their frequency was very high. Furthermore, carbapenem resistance was negligible. Because of drug-resistant P. aeruginosa isolates, it is vital to monitor ICU centers.

Article History

Received: April 10, 2022; Accepted: June 13, 2022; Published: June 29, 2022